This company has shut down. OriCiro Genomics is no longer operating.
Explore the Startup GraveyardOriCiro Genomics develops and commercializes cell-free synthesis and amplification technologies of large DNA molecules.
OriCiro Genomics's investors include UTEC - The University of Tokyo Edge Capital Partners, ITOCHU Technology Ventures, Japan Finance Corporation, Asahi Kasei.
OriCiro Genomics is headquartered in Tokyo, Japan.
OriCiro Genomics develops and commercializes cell-free synthesis and amplification technologies of large DNA molecules.
OriCiro Genomics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OriCiro Genomics — Funding & Investors." VCBacked, June 5, 2022, https://www.vcbacked.co/company/oriciro-genomics. Accessed August 14, 2026.
VCBacked. (2022). OriCiro Genomics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/oriciro-genomics
{{cite web |title=OriCiro Genomics — Funding & Investors |url=https://www.vcbacked.co/company/oriciro-genomics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated